You are here

  • Home
  • Archive
  • Volume 81, Issue 12
  • Correspondence on ‘Long-term efficacy and safety of canakinumab in patients with colchicine-resistant familial Mediterranean fever: results from the randomised phase III CLUSTER trial’

Article metrics

Article menu

Download PDFPDF

Correspondence
Correspondence on ‘Long-term efficacy and safety of canakinumab in patients with colchicine-resistant familial Mediterranean fever: results from the randomised phase III CLUSTER trial’
Free

 

Online download statistics by month:

Online download statistics by month: September 2020 to April 2025

AbstractFullPdf
Sep 2020898823
Oct 202021721439
Nov 202010810812
Dec 2020191913
Jan 2021434116
Feb 202116166
Mar 2021454416
Apr 2021883
May 202152516
Jun 202128283
Jul 202139398
Aug 202136367
Sep 2021212117
Oct 2021434133
Nov 2021373920
Dec 202180792
Jan 202237369
Feb 202231315
Mar 202230304
Apr 202228284
May 2022272710
Jun 202227273
Jul 202230307
Aug 202234335
Sep 202228286
Oct 2022373613
Nov 202230730847
Dec 202229329227
Jan 2023596033
Feb 202348489
Mar 2023323118
Apr 2023252534
May 2023595935
Jun 2023181810
Jul 2023181822
Aug 2023212120
Sep 2023353517
Oct 2023353522
Nov 2023282819
Dec 202318189
Jan 2024262610
Feb 2024131311
Mar 2024111162
Apr 2024303223
May 2024222216
Jun 202417179
Jul 2024222217
Aug 2024161614
Sep 2024161715
Oct 2024202114
Nov 2024343413
Dec 2024181816
Jan 202517178
Feb 202524245
Mar 2025333
Apr 2025664
Total24812473852